Status:
COMPLETED
Hyperthermia Combined With Immune Checkpoint Inhibitor Therapy for Advanced Gastrointestinal Tumours
Lead Sponsor:
Pengyuan Liu
Collaborating Sponsors:
Zhejiang Hospital
Conditions:
Gastrointestinal Tumor
Eligibility:
All Genders
18-75 years
Phase:
PHASE1
PHASE2
Brief Summary
Gastrointestinal tumours (GITs) are the most common and fatal cancers worldwide; 96% of GITs show the microsatellite-stable (MSS)/proficient mismatch repair (pMMR) phenotype, and these tumours have a ...
Detailed Description
The specific treatment process is shown in the trial flow diagram. The patients underwent WIRA whole-body hyperthermia on days 1 and 8 of each HIT cycle. On day 2 (24 h after hyperthermia on day 1), 2...
Eligibility Criteria
Inclusion
- Patients with advanced GIT who have previously received third-line or above treatment.
- Patients are aged 18-75.
- Patients with at least one measurable tumor lesion.
- Patients' all physiological indexes meet the HIT requirements.
Exclusion
- Patients have participated in other clinical trials within 4 weeks before enrollment.
- Patients contraindicate to whole-body hyperthermia.
- Patients contraindicate to immunotherapy.
- Patients cannot fully cooperate with HIT and follow-up.
- Pregnant or lactating women.
- Other circumstances may affect the results.
Key Trial Info
Start Date :
June 1 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2023
Estimated Enrollment :
18 Patients enrolled
Trial Details
Trial ID
NCT06022692
Start Date
June 1 2020
End Date
August 1 2023
Last Update
September 5 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Zhejiang Hospital
Hangzhou, China